 |
|
|
| |
Treatment of non-cirrhotic HCV genotype 4 infected patients with 8 weeks of
ledipasvir/sofosbuvir: an open-label, multicenter clinical trial
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Anne Boerekamps1, Thomas Vanwolleghem2,3, Marc van der Valk4, Guido E. van den Berk5, Marjo van Kasteren6, Dirk Posthouwer7, Ton Dofferhoff8, Bart van Hoek9, Dewkoemar Ramsoekh10, Janke Schinkel11, Eric Florence12, Joop E. Arends13, Bart J. Rijnders1
1Internal Medicine and Infectious Diseases, Erasmus MC, Rotterdam, the Netherlands, 2Gastroenterology and Hepatology, University Hospital Antwerp, Antwerp, Belgium, 3Gastroenterology and Hepatology, Erasmus MC, Rotterdam, the Netherlands, 4Infectious Diseases, Amsterdam Infection and Immunity Institute, Academic Medical Center, Amsterdam, the Netherlands, 5Internal Medicine and Infectious Diseases, OLVG Oost, Amsterdam, the Netherlands, 6Internal Medicine and Infectious Diseases, Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands, 7Internal Medicine and Infectious Diseases, Maastricht Universitair Medisch Centrum+, the Netherlands, 8Internal Medicine and Infectious Diseases, Radboud Universitair Medisch Centrum, Nijmegen, the Netherlands, 9Gastroenterology and Hepatology, Leiden University Medical Center, The Netherlands, 1Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands, 11Medical Microbiology, Section of Clinical Virology, Academic Medical Center, Amsterdam, the Netherlands, 12Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium, 13Internal Medicine and Infectious Diseases, Universitair Medisch Centrum Utrecht, the Netherlands
|
| |
|
|
|
|
|
